PLEASE WATCH OUR VIDEOS TO LEARN MORE.  A SYNOPSIS FOR EACH VIDEO AND LINKS TO YOUTUBE ARE PROVIDED BELOW

The “SHALTech_About_Us” video provides a brief history about how the company got started, a short description about the SHAL drug design platform, and more details about how the mechanisms of actions were determined. It can also be watched by clicking on the “Summary” slider (page 12) above in the slide show (opens in new tab) or by clicking on the image for the video in the footer (opens in light box on same page).

The “Designing a SHAL” video describes the Selective High Affinity Ligand (SHAL) drug design strategy that was developed at Lawrence Livermore National Laboratory by our CEO Rod Balhorn originally for bio-security applications of interest to DOE and DHS, and later with clinical teams at University of California Davis Cancer Center for cancer therapeutics and diagnostic applications.  It can also be watched by clicking on the “The SHAL Platform” slider (page 1) above in the slide show (opens in new tab) or by clicking on the image for the video in the footer (opens in light box on same page).

The “SH7139’s Multi-Mechanisms of Action” video describes the unusual way that this drug is able to kill tumor cells selectively and at very low doses, including inducing a natural vaccine-like immune response against the tumor that is durable and long-lasting.  It can also be watched by clicking on the “SH7139’s Target is unique” slider (page 3) and SH7139 employs multiple mechanisms to kill cancer cells selectively” (page 5) above in the slide show (opens in new tab) or by clicking on the image for the video in the footer (opens in light box on same page).